87 results about "Ingestion" patented technology

Disclosed herein are immediate release oral dosage forms that contain abuse-deterrent and abuse-resistant features. In particular, the disclosed dosage forms can provide deterrence of abuse by ingestion of multiple individual doses. The disclosed dosage forms can likewise provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses. The dosage forms may also exhibit abuse resistant properties when physically manipulated, and also when physically manipulated and then administered in a manner not consistent with oral dosing. The dosage forms may also exhibit abuse resistant properties when administered in a manner intended to result in administration of the esketamine in a higher than therapeutic dose.

Jaw health systems and methods are described in which headphone devices are used to generate metrics related to the jaw health of a user. In one aspect, headphone devices worn on either side of the jaw may each determine the number of bites and chews of a user during an ingestion process and may then generate an imbalance metric. In one aspect, the headphone devices may be used to determine a food or substance toughness during the ingestion process.

Although compounds for treating or ameliorating malignant diseases have been proposed, patients had to endure a large burden since many of such compounds could not be orally ingested. Mangiferin has an effect of ameliorating malignant diseases through oral ingestion. However, such effect is minor and realistically it was not easy to ingest mangiferin. Further, in order to develop more effective pharmaceutical agents and the like for treating malignant diseases, it has been considered constantly necessary to obtain new or improved forms of an existing medical agent for inhibiting kinases such as NIK. A compound represented by formula (11) has an effect of ameliorating malignant diseases through oral ingestion, and can exhibit said effect with an amount less than that for mangiferin.

The present disclosure provides a biodegradable device that is administered to a patient in the form of a compact, ingestible package. The device is self-expandable within the stomach upon contact with liquid to assume an expanded bulk structure within the stomach. The device has a folded configuration that facilitates ingestion by the patient and is designed to unfold and self-expand within the stomach upon ingestion due to expansion of a plurality of expandable cells comprising one or more gel-forming materials. The present disclosure provides such a device, methods of manufacturing the same, and building blocks thereof.

A composition for use in treating or preventing colorectal cancer (CRC) comprising or a fraction of Lactococcus lactis supernatant having a molecular weight greater than 100 kDa which may be obtained by filtration through a 100 kDa molecular weight filter. The composition also comprises a physiologically acceptable excipient and the fraction may be a protein fraction of the L. lactis supernatant. The composition may be formulated for oral ingestion, a powder, liquid, paste, cream, tablet, capsule, or caplet or in a food or beverage item. Additionally, the composition may be formulated in a daily dosage. Also claimed is a kit for treating or preventing colorectal cancer wherein a first container comprises the fraction of L. lactis culture supernatant.

The invention discloses a cascade targeted drug delivery system as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention designs a drug delivery system with a cascade targeting function, and the drug delivery system is used for delivering a phosphodiesterase 4 inhibitor A5. Through polypeptide modification and exosome fusion, phagocytosis and ingestion of cells to a drug delivery system are promoted, and the bioavailability of the drug is significantly improved. The drug delivery system shows excellent in-vivo lung targeting, can effectively inhibit the aggravation of inflammatory infiltration in the lung, and plays a role in treating acute lung injury. The invention provides a new strategy for improving the targeting property and the utilization rate of the medicine, provides a new medicine for treating the acute lung injury, and has a wide application prospect and an extremely high application value.

The present invention relates to a colon cleansing composition with improved ease of administration. The composition minimizes side effects caused by excessive ingredient content in conventional colonic laxatives while providing equivalent or superior intestinal cleansing efficacy, thereby remarkably improving patient compliance and ingestion convenience. In addition, as an uncoated tablet requiring no separate coating processes, a preparation that maintains the quality of tablets such as rapid disintegration and does not have a bitter taste can be provided. The present invention provides a pharmaceutical formulation comprising the colon cleansing composition with improved ease of administration and a method for colon cleansing using the formulation, thereby realizing a patient-centered colon cleansing process and ultimately greatly contributing to the improvement of colonoscopy quality.

This invention discloses a traditional Chinese medicine composition with calming and sleep-aiding effects and its preparation method, relating to the field of pharmaceutical technology. The traditional Chinese medicine composition with calming and sleep-aiding effects comprises the following raw materials in parts by weight: 15-25 parts of vetiver volatile oil, 15-25 parts of valerian volatile oil, 8-12 parts of sandalwood volatile oil, 8-12 parts of cyperus rotundus volatile oil, 8-12 parts of albizia julibrissin bark volatile oil, 5-8 parts of orange blossom volatile oil, 8-12 parts of polygala tenuifolia volatile oil, 8-12 parts of schisandra chinensis volatile oil, 5-8 parts of jasmine volatile oil, and 500-520 parts of fractionated coconut oil. This invention also provides a method for preparing the traditional Chinese medicine composition with calming and sleep-aiding effects, effectively solving the problems of existing sleep aid products that easily cause liver and kidney metabolic burden, gastrointestinal irritation, uncontrollable dosage of active ingredients, and ingestion of ineffective ingredients.

The present invention relates to the use of an s100a8 / a9 and complement 3 inhibitor in the preparation of a drug for treating or preventing cachexia. The treatment or prevention of cachexia comprises increasing the body weight, lean body mass and fat mass, and increasing food intake in a cachectic subject, or preventing fat mass consumption, slowing the rate of body weight loss, the rate of fat mass loss and the rate of lean body mass loss, counteracting anorexia, muscle strength loss, fatigue and body weight loss, or improving abnormal biochemical results. Provided is a new understanding for the mechanism of energy balance regulation in cancer cachexia, with an emphasis on the effects of S100a8 / a9 and C3 in cancer cachexia. The inhibition of S100a8 / a9 and complement 3 can promote fat recovery and increase food intake. Particularly, it is verified that an S100a8 / a9 inhibitor can prevent body weight loss, especially adipose tissue loss, in a cachectic subject, and significantly increases food intake in the subject.

The invention discloses a non-sterilization type mildew-proof and antibacterial material capable of dynamically responding to thallus proliferation as well as a preparation method and application of the non-sterilization type mildew-proof and antibacterial material. The material comprises polyvinyl alcohol, carboxymethyl cellulose or a salt thereof and metal ions, and the polyvinyl alcohol, the carboxymethyl cellulose or the salt thereof are bridged through the metal ions; the metal ions comprise Li < + >. The material disclosed by the invention takes Na < + > released by thallus proliferation as a signal medium, releases Li < + > as required through a coordination-dissociation process, and further induces thallus cells to actively ingest Li < + > through metabolic deception of occupying a potassium ion channel by utilizing a hydration radius of Li < + > similar to K < + > according to the metabolic demand of sodium excretion and potassium ingestion in the thallus proliferation process; on one hand, bacterial cell replication lacks essential nutrient substance K < + >, and finally gradually declines; on the other hand, protein space conformation is changed and inactivated by capturing water molecules of intracellular protein, and the two aspects have a synergistic effect, so that the efficient mildew-proof and antibacterial effects of Li < + > at low concentration can be realized, and the effect is lasting.

Described herein is a controlled release pet food composition comprising: a matrix comprising: a fibrous component comprising a high solubility fiber source and a low solubility fiber source, and a polyphenol source; wherein the matrix is adapted to deliver the polyphenol source to the lower gastrointestinal (GI) tract of a mammal upon uptake by the mammal. Methods of making and using these compositions are also described.

Introduced herein is an ingestible device capable of delivering a drug directly to tissues along the digestive tract. Administration of the drug stored in the ingestible device can be achieved through a combination of features. The ingestible device can include a plunging mechanism to which a needle is connected and a dissolvable trigger mechanism that holds the plunging mechanism in a first position. After ingestion, the trigger mechanism can be exposed to bodily fluids to cause dissolution. When the trigger mechanism dissolves, the plunging mechanism can move from the first position to a second position, thereby extending the needle into the tissue in which the ingestible device is housed. Second, the needle can also dissolve upon exposure to bodily fluids to ensure safe passage of the ingestible device through the digestive tract.

The invention relates to the technical field of carp culture, in particular to a culture method for carps in a high water temperature period and application of the culture method. According to the method, a breeding period is divided into an earlier stage, a high water temperature period and a later stage according to water temperature, and floating expanded compound feed, granular compound feed and high-energy floating expanded compound feed are fed respectively; the feeding rate, feeding times and dissolved oxygen of the three stages are controlled. The invention further provides application based on the breeding method. The breeding period is divided according to the water temperature, different feeds are fed in stages, and the feeding rate, the feeding frequency and the dissolved oxygen amount are controlled in stages, so that the damage and death conditions caused by ingestion of the carps in the high-water-temperature period are reduced; the carps can grow quickly in the early stage, liver and gall function health care is conducted, good ingestion and growth speed is kept in the high-water-temperature period, and high-speed growth and weight gaining are conducted in the later stage; the survival rate in the high-water-temperature period, the weight increment and the growth speed in the whole process are remarkably improved, and the problems that the growth performance and the survival rate of carps are low when the carps are cultured in the high-water-temperature period in the southwest region are solved.

A health analysis system and method configured to base sensor measurements on detection of ingestion of a medication by a patient. The health analysis system receives an indicator collected by a first sensor associated to the patient. The indicator identifies a first adherence event at a first indicator time indicating at least a first medication was ingested by the patient. In response to detection of the indicator, first physiological data of the patient is received which was collected by a second sensor. A first wellness indicator is predicted based on the first physiological data of the patient.

The invention provides a pellet feed precise feeding method and system based on animal information feedback, and relates to the technical field of animal feeding. The method comprises the following steps: when an animal reaches an entrance of a feeding area, determining weight information of the animal fed this time through a weighing sensor, and storing the weight information; after the animal arrives at the feeding point, collecting animal identity information according to the ear tag information of the animal; determining the target feeding amount of the feeding, and performing quantitative feeding; determining the weight of the residual feed for feeding this time; determining the actual feed intake of the feeding; and updating the animal identity information. According to the invention, the target feeding amount can be determined based on the animal weight information and the animal identity information, and quantitative feeding is carried out, so that the animal identity information is updated. According to the animal feeding method, the target feeding amount can be dynamically adjusted according to the ingestion condition and weight change of animals, the feed ratio is optimized in an auxiliary mode, the target feeding amount and the accuracy and pertinence of feed ratio determination are improved, and the animal feeding efficiency is improved.

Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. In another embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, carboxymethylcellulose sodium, hydroxypropylmethylcellulose, citric acid monohydrate, disodium hydrogen phosphate, sucralose, sodium methyl parahydroxybenzoate, sodium ethyl parahydroxybenzoate, concentrated hydrochloric acid, sodium hydroxide, and water.

This invention relates to the use of S100a8 / a9 and complement 3 inhibitors in the preparation of medicaments for the treatment or prevention of cachexia, wherein the treatment or prevention of cachexia involves increasing the body weight, lean body mass, fat mass, and food intake of cachectic subjects, or preventing fat loss, slowing the rate of weight loss, slowing the rate of fat mass loss, slowing the rate of lean body mass loss, resisting anorexia, resisting muscle weakness, resisting fatigue, resisting weight loss, and improving abnormal biochemical results. This invention provides a new understanding of the mechanism of energy balance regulation in cancer cachexia, focusing on the roles of S100a8 / a9 and C3 in cancer cachexia. This invention finds that inhibiting S100a8 / a9 and complement 3 can promote fat recovery and increase food intake. In particular, it demonstrates that S100a8 / a9 inhibitors can prevent the loss of body weight, especially adipose tissue, in cachectic subjects and significantly increase their food intake.

The present invention relates to the field of therapy and drug delivery. More specifically, disclosed herein are therapeutic methods and pharmaceutical compositions for treating disorders of blood tissue barrier shielded organs having a large number of populations of post-mitotic neurons, such as organs derived from neural tubes, including the central nervous system and the eye. The disclosed methods and compositions involve topically applying into such organs a combination of an effector component that targets a biological target in a cell, and a saponin component that promotes effective ingestion of the effector component into the cell and / or enhances effective path steering of the effector component within the cell in which the biological target is present. For example, the effector component may be an oligonucleotide therapeutic agent targeting gene products associated with CNS and / or disorders of the eye. Due to the cellular uptake stimulating effect and / or endosomal escape enhancing effect of the saponin component, the neuropharmaceutical and ophthalmic compositions presented herein for topical administration into the CNS and / or eye, respectively, may be formulated with lower concentrations of effector components and / or in smaller volumes, this brings safety benefits to the neurons and the comfort of the patient.

Beta-hydroxybutyrate compositions formulated for ingestion by oral delivery as a beverage, or as a dietary supplement for addition to water or beverage, include a liquid carrier, such as water, milk, drinkable liquid, coconut water, watermelon water, or electrolyte water, and beta-hydroxybutyrate. The beta-hydroxybutyrate composition can include enantiomerically pure R-beta-hydroxybutyrate or a non-racemic mixture enriched in R-beta-hydroxybutyrate relative to S-beta-hydroxybutyrate. Alternatively, the beta-hydroxybutyrate composition can include enantiomerically pure S-beta-hydroxybutyrate or a non-racemic mixture enriched in S-beta-hydroxybutyrate relative to R-beta-hydroxybutyrate. Alternatively, the beta-hydroxybutyrate composition can include a racemic mixture of R-beta-hydroxybutyrate and R-beta-hydroxybutyrate. The beta-hydroxybutyrate compositions comprise beta-hydroxybutyric acid and optionally one or more beta-hydroxybutyrate salts or esters.

The invention relates to an efficient energy supply type laboratory mouse feed which comprises the following components in percentage by weight: 20-40% of corn, 10-30% of wheat, 1-5% of wheat middling, 4-10% of soybean meal, 2-8% of fish meal, 2-6% of chicken meal, 1-10% of soybean hull, 1-5% of soybean oil, 1-5% of lard, 0.5-2% of stone powder, 0.5-1.5% of calcium hydrophosphate, 2-5% of premix, 1-5% of MCT microcapsule powder and 0.5-2% of glutamine. The stability of MCT is improved through a microencapsulation method, the activity of glutamine is reserved through an embedding method, the synergistic effect of MCT microcapsule powder and glutamine is utilized, meanwhile, lard oil and fat raw materials are added, high-temperature steam is used for curing materials in the production process, the fragrance of the feed is further improved, the palatability of the feed is jointly improved, the food intake of laboratory mice is not affected, and the production cost is reduced. The utilization efficiency of the feed is improved; the experimental mouse feed can reduce body fat and improve blood lipid level, can effectively prolong exhaustion time of mice, and is suitable for cultivation and maintenance of special experimental animals such as intestinal injury models and immunodeficiency models.

This invention belongs to the field of pharmaceutical technology, specifically relating to the use of a 4-(4-diethylamino-1-methylbutanamino)-7-chloroquinoline derivative or its pharmaceutically acceptable salt, or its tautomer, meso compound, racemic compound, enantiomer, diastereomer, or pharmaceutical composition thereof as an active ingredient in the preparation of drugs for the prevention or treatment of obesity and obesity-related metabolic diseases. The 4-(4-diethylamino-1-methylbutanamino)-7-chloroquinoline derivative of this invention has significant therapeutic effects on obesity and related metabolic diseases. In obese mice induced by a high-fat diet and high-fructose water intake, gavage administration for 6 weeks showed that, compared with the high-fat control group, it inhibited more than 70% of the mice's weight gain, with no significant difference in food intake and water intake, demonstrating good clinical application prospects.

An orally administrable drug powder composition which forms a gastro-retentive RAFT having at least two trigger pulses is provided. The composition contains, at a minimum, (a) at least one drug in an immediate release pulse release form; (b) at least one drug in a delayed trigger release form; (c) at least one non-toxic gas generating agent and (d) a RAFT system, wherein following oral ingestion, the composition provides a self-assembling gastro-retentive RAFT having entrapped therein, the at least one drug of (a) and (b) and the gas generated in situ by the non-toxic gas generating agent, thereby providing a floating gastro-retentive RAFT having a dual pulse system wherein at least the second pulse is a trigger pulse and which retains the at least one drug in the stomach for at least about 3 hours, provided that the composition does not include a gamma hydroxybutyrate and its salts, hydrates, tautomers, or solvates, or complexes thereof.

This invention discloses the application of a high-N-acetylglycine-producing *Lactobacillus reuteri* strain in alleviating obesity-related metabolic diseases, belonging to the field of microbial technology. The *Lactobacillus reuteri* NO1 strain of this invention (…) Limosilactobacillus reuteri (NO1) possesses the ability to produce N-acetylglycine in vitro. This strain can inhibit weight gain in obese mice without affecting food intake; improve glucose tolerance in obese mice while reducing blood glucose, serum insulin, and insulin resistance index; regulate liver triglycerides in obese mice, and alleviate liver tissue damage. The *Lactobacillus reuteri* strain described in this invention has very broad application prospects for preparing anti-obesity pharmaceutical compositions and fermented foods.

The invention relates to a device comprising an expandable hollow hydrogel tube encapsulated by an ingestible capsule to enable the targeted delivery of large molecules such as biologics to the gastrointestinal (GI) mucosa. Upon ingestion, the capsule is arranged to release the hydrogel tube in the GI tract, where the hydrogel tube expands from a first configuration to a second configuration upon hydration. In its expanded state, the hydrogel tube exerts an outward radial force on the lining of the GI tract. In some embodiments, the outward-facing surface of the hydrogel tube comprises microneedles. The invention further relates to a hydrogel resin comprising: gelatin or poloxamer 407; a neutralisation agent; acrylic acid or sodium acrylate; a crosslinker; a photoinitiator; and a photoabsorber. The hydrogel tube of the invention may be produced by bioprinting and photo-crosslinking said hydrogel resin.

[PROBLEM] To provide a formulation that is safe for ingestion over a long period of time and can improve the enterobacterial flora or can enhance the barrier function of the intestinal mucosa.[SOLUTION] The present invention is an enteric capsule formulation for improving enterobacterial flora containing nicotinamide mononucleotide as an active ingredient.

The invention relates to the technical field of aquaculture and biology, in particular to an SIFamide neuropeptide gene and application of the SIFamide neuropeptide gene in promoting growth of litopenaeus vannamei. The litopenaeus vannamei SIFamide gene is shown as a nucleotide sequence of SEQ ID NO: 1. The SIFamide neuropeptide gene is applied to the growth and intestinal peristalsis of the litopenaeus vannamei. The nucleotide sequence of the interference fragment for inhibiting the SIFamide neuropeptide gene is as shown in SEQ ID NO: 4. After the nucleotide sequence (double-stranded RNA) of the interference fragment is applied to the litopenaeus vannamei in an intramuscular injection manner, the weight increase of the litopenaeus vannamei is obviously accelerated and the intestinal peristalsis frequency is obviously improved under the condition that the expression of the SIFamide gene is inhibited. According to the method, damage to the litopenaeus vannamei is small, normal ingestion, molting, inhabiting and other behaviors of the litopenaeus vannamei are not affected, and the action effect is stable.

An inflatable member (201, 301) for an ingestible device (200, 300) includes a first section (202, 302) and a second section (204, 304). The first section includes a plurality of pockets (202a, 202b, 202c, 302a, 302b, 302c) that are partially separated from one another and fluidly coupled together by foldable joints (202ab, 202bc, 302ab, 302bc) located therebetween. The plurality of pockets are configured to contain a first substance (212, 312). The second section includes a reservoir (204a, 304a) configured to contain a second substance (214, 314). The first section is configured to fold through the foldable joints after being filled with the first substance such that the pockets are arranged in a coiled or overlapping configuration. The inflatable member is structured to inflate upon ingestion of the ingestible device to occupy space in a GI tract of a subject.

The application discloses application of cloud weiling volatile oil in preparation of digestion-aiding and appetite-stimulating drugs. A preparation method of the cloud weiling volatile oil is as follows: cloud weiling medicinal materials are crushed, 8-10 times of water is added, and the mixture is refluxed at 90-100 DEG C for 3-5 hours, then the cloud weiling volatile oil is collected by a volatile oil extractor, dehydrated by adding anhydrous sodium sulfate, centrifuged, filtered, and obtained. The application provides application of the cloud weiling volatile oil in preparation of digestion-aiding and appetite-stimulating drugs. Experiments prove that the cloud weiling volatile oil can promote intestinal peristalsis, promote secretion of GAS and MTL, enhance pepsin activity and secretion, and increase food intake, and has the prospect of becoming a digestion-aiding and appetite-stimulating drug.

The invention discloses an sNPF gene and application of an inhibitor of the sNPF gene in prevention and control of beet armyworms, and belongs to the technical field of biology. The sNPF gene of the beet armyworm is silenced through an RNA interference technology, and the sNPF is found to play an important regulation role in ingestion, growth and development and energy metabolism of larvae; the sNPF gene silencing obviously reduces the feeding amount and the body weight growth rate of the larvae, and increases the death rate of the larvae under hunger stress; in addition, silence of the sNPF gene also significantly affects the content of glycometabolism substances in the larva body. The sNPF is found to be a key factor for regulating and controlling the physiological process of beet armyworm larvae, has the potential of serving as a new target for pest control, and provides a theoretical basis for prevention and control of beet armyworms.

The invention relates to a device comprising an expandable hollow hydrogel tube encapsulated by an ingestible capsule to enable the targeted delivery of large molecules such as biologics to the gastrointestinal (GI) mucosa. Upon ingestion, the capsule is arranged to release the hydrogel tube in the GI tract, where the hydrogel tube expands from a first configuration to a second configuration upon hydration. In its expanded state, the hydrogel tube exerts an outward radial force on the lining of the GI tract. In some embodiments, the outward-facing surface of the hydrogel tube comprises microneedles. The invention further relates to a hydrogel resin comprising: gelatin or poloxamer 407; a neutralisation agent; acrylic acid or sodium acrylate; a crosslinker; a photoinitiator; and a photoabsorber. The hydrogel tube of the invention may be produced by bioprinting and photo-crosslinking said hydrogel resin.